Inceptionr LLC Acquires New Position in Pfizer Inc. $PFE

Posted by Chris Copeland on Mar 11th, 2026

Inceptionr LLC bought a new position in Pfizer Inc. (NYSE:PFE – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 19,784 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $2,270,157,000. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after purchasing an additional 6,045,763 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after purchasing an additional 5,662,309 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of Pfizer by 75.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after buying an additional 3,722,531 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.12 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $154.22 billion, a PE ratio of 19.94 and a beta of 0.47. The firm’s 50 day moving average price is $26.38 and its 200-day moving average price is $25.49. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the business posted $0.63 earnings per share. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Friday, January 23rd were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date was Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Scotiabank started coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. TD Cowen restated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. Finally, UBS Group assumed coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.05.

Check Out Our Latest Stock Report on PFE

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Positive Phase‑2 readout for tilrekimig (PF‑07275315) — the study met its primary endpoint (EASI‑75 at Week 16) and Pfizer plans late‑stage testing, which materially strengthens the company’s dermatology pipeline and future growth prospects. Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate-to-Severe Atopic Dermatitis Pfizer’s eczema drug meets main goal in mid-stage trial
Neutral Sentiment: FDA approved leucovorin for a rare genetic condition but not for autism — important regulatory news for the sector but not directly tied to Pfizer’s marketed products or near‑term revenue. FDA Approves Leucovorin—But Not For Autism
Neutral Sentiment: Patent activity around tafamidis (a competing transthyretin amyloidosis drug) and related market moves lifted other small caps — the BridgeBio story signals shifting patent dynamics that could influence competitive positioning over time but the impact on Pfizer is uncertain. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
Neutral Sentiment: BioNTech cofounders stepping down rattled biotech sentiment broadly; this is sector noise that can increase volatility but does not directly affect Pfizer’s fundamentals. BioNTech Cofounders To Step Down. Stock Crumbles.
Negative Sentiment: Investor concern over Pfizer’s payout ratio (reported >100%) and a quarterly loss raised the specter of dividend pressure — this remains a key negative risk that can cap upside and prompt selling. Pfizer’s Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
Negative Sentiment: Despite the positive eczema data, some reports noted shares dipped earlier — signaling profit‑taking and investor skepticism that new pipeline data will immediately translate to material revenue. That caution can mute sustained rallies. Pfizer shares dip despite positive trial results for skin condition drug

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.